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Aims: Cardiovascular disease is a leading cause of morbidity and mortality. Smooth 
muscle cells (SMC) comprising the vascular wall can switch phenotypes from contractile 
to synthetic, which can promote the development of aberrant remodelling and intimal 
hyperplasia (IH). MicroRNA21 (miR21) is a short, noncoding RNA that has been 
implicated in cardiovascular diseases including proliferative vascular disease and 
ischaemic heart disease. However, its involvement in the complex development of 
atherosclerosis has yet to be ascertained. 
Methods: Smooth muscle cells (SMC) were isolated from human saphenous veins (SV). 
miR21 was overexpressed and the impact of this on morphology, proliferation, gene 
and protein expression related to synthetic SMC phenotypes monitored. 
Results: Overexpression of miR21 increased the spread cell area and proliferative 
capacity of SVSMC and expression of MMP1, whilst reducing RECK protein, 
indicating a switch to the synthetic phenotype. Furthermore, PDGFBB (a growth factor 
implicated in vasculoproliferative conditions) was able to induce miR21 expression via 
the PI3K and ERK signalling pathways. 
Conclusion: This study has revealed a mechanism whereby PDGFBB induces expression 
of miR21 in SVSMC, subsequently driving conversion to a synthetic SMC phenotype, 
propagating the development of IH. Thus, these signaling pathways may be attractive 
therapeutic targets to minimise progression of the disease. 
 
Page 2 of 30
http://mc.manuscriptcentral.com/tandf/tbmb
IUBMB Life
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 O
nly

MicroRNA21, PDGF, saphenous vein, smooth muscle cell, phenotype, remodelling 
 !
BIRC3, baculoviral IAP repeat containing 3; CABG, coronary artery bypass grafting; 
CAD, coronary artery disease; CVD, cardiovascular disease; EC, endothelial cell; 
ERK1/2, extracellular regulated kinase 1/2; GAPDH, glyceraldehyde3phosphate 
dehydrogenase; IH, intimal hyperplasia; IL, interleukin; IL1R2, interleukin1 receptor 2; 
IMA, internal mammary artery; ITGB2, integrin subunit beta 2; KDR, kinase insert 
domain receptor; MGM, minimal growth medium; miRs, microRNAs; MMP, matrix 
metalloproteinase; MT1MMP, membrane type 1 matrix metalloproteinase; PCI, 
percutaneous coronary intervention; PDGFBB, plateletderived growth factor BB; 
PPARG, peroxisome proliferatoractivator receptor gamma; RECK, reversion inducing 
cysteine rich protein with Kazal motifs; RQ, relative quantification; SMC, smooth muscle 
cell; SV, saphenous vein; VWF, von Willibrand factor. 
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Despite continued advances in knowledge and therapeutic strategies, atherosclerosis 
remains the leading cause of cardiovascular disease (CVD) around the world [1]. 
Atherosclerosis is a chronic, progressive inflammatory disorder which involves 
interactions of different vascular cell types that are the underlying cause of angina, 
coronary artery disease (CAD) and stroke [2]. Atherosclerosis in the coronary arteries can 
block the blood supply to the heart tissue, causing myocardial infarction and necessitating 
vascular reconstruction. 
The advent of percutaneous coronary intervention (PCI) has improved treatment options 
for patients, yet coronary artery bypass grafting (CABG) remains the mainstay for 
patients with multivessel disease and impaired ejection fraction [3]. The commonly used 
bypass conduits for CABG are the autologous internal mammary artery (IMA) and the 
saphenous vein (SV), with the SV graft remaining popular for multiple grafts due to its 
ease of harvesting and ready availability. However, during the first year postCABG up 
to 15% of SV grafts fail with an expected 45% attrition rate each year thereafter [4]. 
Therefore, in 10 years SV graft failure rates are close to 50% and approximately 31% of 
all CABG surgeries in the United Kingdom necessitate reintervention [5]. Conversely, 
8095 % of IMA grafts remain patent at 10 years [6]. 
The underlying pathological lesion of SV graft stenosis is the characteristic development 
of intimal hyperplasia (IH). IH can be detected approximately 46 weeks following SV 
grafting [7] and this can be further augmented by continued atherosclerotic lesion 
development in the vein graft within one year following vein implantation [8].   
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Smooth muscle cells (SMC) constitute the major cell type in the blood vessel wall, and 
their principal role is to maintain vascular tone and vessel homeostasis. In health, SMC 
exist in a contractile, differentiated state with a low turnover rate, but following injury 
and in response to circulating cytokines and growth factors, they switch to a synthetic 
phenotype that is characterised by increased proliferation, loss of contractility, and 
secretion of extracellular matrix degrading enzymes. This encourages migration of SMC 
into the intimal layer of the blood vessel, thus initiating a remodelling event as an 
adaptive response that ultimately can exacerbate the development of intimal hyperplasia 
and restenosis [9]. 
Plateletderived growth factor BB (PDGFBB) is a potent SMC mitogen and 
chemoattractant that induces cellular dedifferentiation into a synthetic phenotype, 
increasing proliferation and migration into the intima such as is evident in atherosclerosis 
and restenosis [10, 11]. In addition to being secreted from platelets, PDGF is secreted by 
endothelial cells (EC) and SMC [12]. PDGFBBinduced SMC dedifferentiation is driven 
through the phosphoinositide3kinase/AKT and mitogenactivated protein kinase 
extracellular regulated kinase 1/2 (ERK1/2) intracellular transduction pathways [13]. As 
increased SMC migration and proliferation constitute the cornerstone of IH and SV graft 
failure, PDGFBB is implicated in its progression [14]. 
MicroRNAs (miRs) are short, noncoding RNAs that negatively regulate gene 
expression. Emerging evidence reveals miR21 to be one of the most dysregulated 
miRNAs in the cardiovascular system. miR21 is expressed in most cardiovascular cell 
types including vascular SMC [15] and can mediate the pathological development of 
neointimal hyperplasia [15], atherosclerotic lesions [16], and cardiac hypertrophy and 
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fibrosis [17, 18]. Indeed, miR21 expression is reportedly elevated in human 
atherosclerotic plaques [19] and, at least in murine models, is upregulated and mediates 
neointimal formation following vein grafting [20]. 
Despite advances in modern therapies, vein graft failure is still a significant problem that 
requires identification of novel targets for development of new therapeutics to ameliorate 
adverse vascular remodelling. Thus, the aim of this study was to explore a relationship 
between miR21 and PDGF in the cellular mechanisms underlying SVSMC dysfunction 
that occurs in vein graft failure.  
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Human SV specimens were obtained from patients undergoing elective CABG surgery at 
the Leeds General Infirmary. Local ethical committee and informed, written patient 
consent was obtained and the study conformed to the Declaration of Helsinki. SVSMC 
were cultured using an explant technique as previously described [21]. As we have 
previously demonstrated profound phenotypic changes in SVSMC isolated from patients 
with Type 2 diabetes [2224], all experiments were performed using cells cultured from 
patients without a diagnosis of diabetes, and used between passages 3 and 5. 
	
!
Subconfluent SVSMC were transfected with 30 nM premiR21 (hsamiR215p; 
AM17100) or its associated negative control (AM17110; “premiRnegative”) using 
Lipofectamine 2000 (all Life Technologies, Paisley, UK). Cells were harvested after 72 h 
and endpoints determined (cell morphology, Factin staining, RNA isolation) or 
proliferation assays performed. 

Images of subconfluent cells were captured under the light microscope at x100 
magnification. For each patient population, 50 randomly selected cells were measured by 
tracing the cell boundaries and areas were calculated using ImageJ software 
(https://imagej.nih.gov/ij/) [25]. For cytoskeletal assessment, cells were cultured on glass 
coverslips in medium containing 0.4% foetal calf serum (minimal growth medium, 
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MGM) for 72h. After fixation in 4% paraformaldehyde, Factin fibres were labelled using 
rhodamine phalloidin (1:40) as previously described [26]. Fluorescence images were 
captured using an LSM510 upright confocal microscope at x200 magnification. 
!
SVSMC proliferation was determined by in vitro counting of live cells in triplicate using 
trypan blue and a haemocytometer as we described previously [22]. 
%	&	'
For quantification of miR21 expression, cellular RNA was used to produce cDNA using 
TaqMan MicroRNA Reverse Transcription System. MiR21 expression levels were 
measured using miR21 TaqMan microRNA assay (Applied Biosystems) and realtime 
PCR performed according to manufacturer’s protocols. Data were analysed using the 
comparative CT method and values normalised to U6 expression. For gene expression 
studies, cellular RNA was extracted and realtime RTPCR was performed in triplicate 
using Applied Biosystems 7500 PCR system and intronspanning human matrix 
metalloproteinase1 (MMP1; Hs00233958_m1), interleukin 1alpha (IL1α; 
Hs00174092_m1), reversion inducing cysteine rich protein with Kazal motifs (RECK; 
Hs01019179_m1) primers and TaqMan® probes. Data are expressed as percentage of 
glyceraldehyde3phosphate dehydrogenase (GAPDH) endogenous control levels 
(Hs99999905_m1) using the formula 2
PCT
 x 100 or to a control sample using the formula 
2
PPCT
. 
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SVSMC from four different patients were transfected with 30 nM premiR21 or 
equivalent premiR negative control. Cellular RNA was extracted and reverse transcribed. 
Expression levels of 84 atherosclerosisrelated genes were quantified using a focused 
SYBR greenbased realtime PCR array (RT2 Profiler Human Atherosclerosis, 
SABiosciences / Qiagen PAHS038ZA12) and the Applied Biosystems 7500 Realtime 
PCR system. PCT vales for the target genes were calculated by subtracting the mean CT 
value (threshold cycle number) of the 5 housekeeping genes on the array from the CT 
value of the target genes. Data are expressed as relative quantification (RQ) values 
compared with the 5 housekeeping genes using the formula RQ=2
PCT
. 
"
Immunoblotting was performed essentially as per our previous protocol [27]. Whole cell 
homogenates were prepared and protein was separated using SDSPAGE 10% 
polyacrylamide gels and transferred to PVDF membranes. Phosphorylation of AKT and 
ERK1/2 was determined by immunoblotting with phosphospecific monoclonal 
antibodies (#9106 mouse, #4060 rabbit respectively). Membranes were reprobed with 
AKT and ERK expression antibodies (#2920 and #4695 respectively, all Cell Signaling 
Technology). For RECK protein, a 7.5% SDSPAGE gel was prepared and αtubulin 
used as a loading control. 
(
All results are expressed as a mean ± SEM. Statistical analysis was performed using 
GraphPad Prism 7 by oneway ANOVA followed by NewmanKeuls multiple 
comparisons posthoc test. Paired ratio ttests were performed on log transforms of all 
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normalised data to test statistical significance where appropriate. P < 0.05 was considered 
statistically significant. 
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)	$	
!(*	(
Cells overexpressing miR21 exhibited an enlarged, rhomboid morphology which was 
visible under phase contrast microscopy (Fig. 1A), accounting for a 1.7fold increased 
spread area relative to control premiRnegative transfected cells (Fig. 1B). This enlarged 
morphology was further emphasised by rhodamine phalloidin fluorescence microscopy, 
which revealed that the Factin cytoskeleton appeared visually intact in these 
morphologically aberrant SMC (Fig. 1C). Cells overexpressing miR21 also exhibited 
increased cell proliferation, resulting in a 1.8fold increase in cell number relative to 
control premiRnegative transfected cells after 4 days (Fig. 1D). 
 ! !    	
	   (*	
(
Using SMC overexpressing miR21, we performed a focused microarray to explore 
expression of 84 potential target genes related to atherosclerosis and cardiovascular 
disease. The pattern of gene expression induced by miR21 overexpression is presented 
in a volcano scatter plot (Fig. 2A). Of the 84 genes studied, 10 genes presented a fold 
change ≥ ± 1.5. MMP1, MMP3, interleukin 1 receptor 2 (IL1R2), peroxisome 
proliferatoractivator receptor gamma (PPARG) and integrin subunit beta 2 (ITGB2) 
displayed ≥ 1.5fold increase in the premiR21 transfected cells relative to control 
premiRnegative transfected SVSMC. Conversely, interleukin1α (IL1A), kinase insert 
domain receptor (KDR), Baculoviral IAP repeat containing 3 (BIRC3), von Willibrand 
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factor (VWF) and interleukin 5 (IL5) showed > 1.5fold decrease in the premiR21 
transfected cells relative to premiRnegative controls (Table 1). 
Genes identified by microarray were subsequently validated using specific TaqMan 
probes and RTPCR using RNA from six different patients, which included the four 
original samples that were analysed by array. In this series of experiments, we confirmed 
a statistically significant increase in MMP1 mRNA expression in the premiR21 
transfected cells versus premiRnegative controls (Fig. 2B). On the contrary, we were 
unable to validate the IL1A data where only a small but nonsignificant reduction was 
evident in the premiR21 transfected cells relative to the control SVSMC (Fig. 2C). 
	
	$#(*	(
RECK is a recognised target of miR21 that is known to be involved in cell proliferation 
[28]. In our study, miR21 overexpression in SVSMC for 72h led to ~50% reduction in 
RECK mRNA expression levels (Fig. 2D), yet there were no detectable changes in RECK 
protein levels at this time point (data not shown). Extended study revealed a ~40% 
reduction in RECK protein levels in response to premiR21 transfection after 8 days (Fig. 
2E,F). 
'+,-	..  	
 $  &  #/
   (*	
(
To identify the potential source of miR21 upregulation in SVSMC we treated cells 
with the potent chemoattractant and mitogen PDGFBB which is known to be increased 
in proliferative vascular disorders [29]. Exposure of SVSMC for 24 h to physiologically 
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relevant (1 ng/ml and 10 ng/ml; [30, 31]) concentrations of PDGF stimulated miR21 
expression; an effect that was maintained up to 72 h (Fig. 3A). 
Binding of PDGF to its cognate receptor results in a signalling cascade that induces 
phosphorylation of both AKT and ERK1/2 [32]. To determine which of these pathways 
was involved in inducing miR21 expression, we used specific pharmacological 
inhibitors. PDGFBB treatment induced phosphorylation of both AKT and ERK1/2 as 
expected and pathwayspecific phosphorylation events were inhibited by pretreating 
with inhibitors of AKT (LY294002) and ERK1/2 (PD98059) pathways (Fig. 3B). 
Inhibiting either pathway independently was able to completely abrogate the induction of 
miR21 expression by PDGFBB, confirming the requirement for both pathways in miR
21 regulation in these cells (Fig. 3C). 
'+,-	..   !! ! 	
 	$  '	  #
$
Having shown that PDGFBB increased miR21 expression (Fig. 3), and that miR21 
overexpression led to an increase in MMP1 mRNA expression and inhibition of RECK 
expression (Fig. 2), we proceeded to seek evidence for a link between PDGF and these 
targets. PDGFBB significantly induced MMP1 mRNA at 24 h in a concentration
dependent manner, although this effect was transient and expression levels returned to 
baseline by 72 h (Fig. 3D). In parallel, RECK mRNA was significantly downregulated in 
a concentrationdependent manner, and this effect was maintained over the full 72 h 
period of study (Fig. 3E). 
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Dysregulation of SMC differentiation is an event critical to the development of CVD. 
The presence of characteristically dedifferentiated SMC in IH is well recognised and thus 
investigations into the mechanisms contributing to this phenotypic reversion are of 
significant clinical importance. Two of the predominant mechanisms for SV graft failure 
are IH and accelerated atherosclerosis. In the present study, we utilised clinically relevant 
human SVSMC and revealed signalling pathways whereby overexpression of miR21 
led to acquisition of a synthetic phenotype.  
	
!(
The importance of miR21 in the cardiovascular system is well recognised. It is 
aberrantly expressed in vascular SMC [15] and EC [33] following vascular injury, and is 
significantly upregulated in human atherosclerotic plaques [19], injured rat carotid 
arteries [15] and following vascular grafting in mice [20]. However, its influence on 
human SVSMC remodelling following bypass grafting is unknown. In this study we 
used an overexpression approach to determine the impact of miR21 on SMC phenotype 
and function in vitro.  
Synthetic SMC in remodelling vessels are known to adopt a rhomboid morphology and 
have a high turnover rate [34]. Both of these features were observed in miR21 over
expressing SVSMC, confirming that miR21 was a driver of this dedifferentiation. 
Given the widespread reporting of miR21 as a protooncogene that increases 
proliferation in a number of pathological models including vascular SMC [15, 35, 36], its 
impact specifically on SVSMC is perhaps unsurprising. In direct contrast however,  
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miR21 has been purported to drive a differentiated, contractile phenotype in human 
pulmonary artery SMC [37] and correlates with expression of smooth muscle 
differentiation genes [38]. Given this disparity, we perceived it was important to validate 
this hypothesis in clinically relevant human SVSMC. Our present data highlight the 
species and cell typespecific nature of miR21’s mechanism of action.  
"!!	

As miR21 overexpressing cells were dedifferentiated, and such SMC are common in 
IH, we proceeded to use a microarraybased approach to identify downstream targets of 
miR21 in SVSMC that may contribute to the development of CVD. IL1A is a pro
inflammatory cytokine that is elevated in atherosclerosis [39], however its regulation by 
miR21 could not be corroborated in SVSMC. In contrast, the array data for MMP1 was 
validated using specific Taqman assays which identified MMP1 as being regulated by 
miR21 in these cells.  
MMPs play an important role in degrading the ECM and can contribute to matrix 
destabilisation [40]. Furthermore, digestion of integrins by MMPs can facilitate SMC 
dedifferentiation [41]. Interestingly, in SVSMC, there was a positive relationship 
between miR21 and MMP1 mRNA expression. Normally, miRs negatively regulate the 
expression of direct gene targets [42]. This suggests that the relationship between miR21 
and MMP1 in SVSMCs is complex and involves an intermediary step whereby the target 
of miR21 firstly inhibits expression of a gene that normally acts as a repressor of MMP1 
expression.  
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Transcriptional regulation of MMPs is complicated, encompassing multiple intracellular 
signalling pathways and transcription factors [43]. RECK is a membranebound MMP 
inhibitor that has been reported to regulate the gelatinases MMP2 and 9, and their 
activator membrane type 1MMP (MT1MMP) [44]. Previous studies have shown that 
miR21 overexpression in various cancer cell lines reduces mRNA and protein levels of 
RECK [45]. Furthermore, in vascular SMC, knockdown of RECK led to increased MMP
2 and 9 expression, and an increase in cell proliferation [46]. In the present study, 
transfection with premiR21 inhibited RECK mRNA expression after 3 days, and RECK 
protein levels after 8 days. Evidence of a direct effect of RECK on MMP1 expression 
remains elusive, thus the relationship in SVSMC is worthy of further investigation. 
'+,-	..!(!	

On the basis of the above evidence, elevated miR21 expression can cause vascular SMC 
dysfunction leading to dedifferentiation, enhanced proliferation and degradation of the 
ECM. MiR21 is known to be elevated in proliferative SMC present in IH and 
atherosclerotic plaques, thus identifying the factor(s) responsible for this elevation is of 
clinical relevance. 
PDGFBB is a potent SMC chemoattractant and mitogen, which can promote SMC 
dedifferentiation and proliferation [10, 11] and is elevated following vascular injury and 
angioplasty [29]. PDGFBB is purported to regulate miR21 in a number of cell types, 
including rat aortic SMC [47]. Our observations of a modest yet consistent upregulation 
of miR21 by PDGFBB in SVSMC that persists over time aligns with this. However, a 
recent study raised the possibility of a more complex relationship whereby miR21 could 
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prevent the mitogenic effects of PDGF [36]. Further experiments examining any 
attenuation of PDGFBB signalling through overexpressing miR21 may answer this 
question.  
Both the PI3K/AKT and ERK1/2 pathways are activated upon binding of PDGFBB to 
its receptor, leading to SMC dedifferentiation [13, 32]. In our study, inhibition of either 
pathway was sufficient to completely ablate miR21 expression by PDGFBB, indicating 
that both pathways are required. Interestingly, miR21 itself can stimulate the AKT 
pathway (via suppression of PTEN; [15, 35]) and the ERK pathway [48] potentially 
causing a positive feedback loop that reinforces the effect of PDGFBB on miR21 
expression.  
Treatment of SVSMC with PDGFBB was sufficient to increase expression of MMP1 
mRNA and reduce expression of RECK. Reports of a relationship between PDGFBB 
and RECK in the literature are lacking, although one study demonstrated that loss of 
RECK in fibroblasts caused a disordered chemotactic response to PDGF [49]. To our 
knowledge, ours is the first report of PDGFBB regulating RECK expression in human 
SMC via upregulation of miR21. The relationship between PDGF and MMP1 is 
however, better recognised and previous studies have reported a positive relationship 
between PDGF and MMP1 [50]. Our data concur with these findings, and further 
suggest a mechanism mediated via miR21.  
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During pathological vascular remodelling, secretion of cytokines and growth factors from 
multiple vascular cell types are increased. Here, we have demonstrated how one such 
growth factor, PDGFBB, controls SVSMC phenotype, at least in part, through miR21. 
This has downstream effects on RECK and MMP1 expression and leads to SVSMC 
dedifferentiation (see Fig. 4 for summary diagram). Targeted inhibition of PDGFBB 
signalling may be a beneficial therapeutic strategy following coronary artery bypass 
grafting to limit postgraft development of neointimal hyperplasia. 
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- 
-  )$ ! 	
  ( A SVSMC were 
transfected with 30nM premiR21 and cultured for 72h. (A) Representative images of 
transfected SVSMC and (B) quantification of spread cell area (n=7, **P<0.01). (C) 
Representative images of the Factin cytoskeleton stained with rhodamine phalloidin. (D) 
After the 72h period, cells were placed in proliferation assays and direct cell counts taken 
after 4 days. Data is presented as a fold increase in cell number from day 0 (n=5, 
**P<0.01). 
-
	
	$	$ (A) 
Volcano plot of the RT2 Profiler Human Atherosclerosis PCR Microarray data. The 
difference in expression level (log 2 scale) is indicated on the xaxis and the yaxis 
indicates statistical significance (log 10 scale). Values located above the horizontal 
dotted line indicate P < 0.05. Only genes that had  ≥ ±1.5fold changes are labelled; 
genes upregulated by miR21 overexpression are indicated in grey and those down
regulated are indicated in black (n=4). The array data was validated using TaqMan® 
intronspanning primers for (B) MMP1 and (C) IL1A (both n=6). (D) Quantification of 
RECK mRNA in SVSMC transfected with premiR21 (or premiRve) for 72 h (n=8). 
(E) Quantification of RECK protein in transfected cells after 8 days (n=5, ***P<0.001). 
(F) Representative immunoblot with αtubulin as a loading control. ***P<0.001, 
**P<0.01, *P<0.05, ns=not significant. 
- 3 '+,-  	
 $  &  #/
5  
'	  #A (A) SVSMC were treated with increasing concentrations of 
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PDGF and miR21 expression quantified after 2472h (n=5, **P<0.01, *P<0.05, ns=not 
significant. (B) SVSMC were treated with the PI3K inhibitor LY294002 (LY; 10µM) 
and ERK1/2 inhibitor PD98059 (PD; 30µM) for 1 h prior to PDGF stimulation (20 min). 
V refers to vehicle control. Representative Western blot demonstrating the efficacy of the 
inhibitors. (C) SVSMC were treated with V, LY or PD for 1 h prior to the addition of 
PDGF. miR21 expression was monitored 48 h later (n=5, *P<0.05). SVSMC were 
treated with increasing concentrations of PDGF and the expression of (D) MMP1 and 
(E) RECK quantified after 2472h (n=5, ***P<0.001, **P<0.01, *P<0.05, ns=not 
significant). 
- 1 '+,- 	 	
 $  (*	(A PDGFBB in the circulation signals 
through both AKT and ERK to upregulate expression of miR21. In turn, this inhibits 
MMP1 and RECK1, and drives a phenotypic switch towards a synthetic SMC such as 
the type prevalent in atherosclerosis and neointimal hyperplasia. 
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